Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia

Lancet

Volumn 356, Issue 9226, 2000, Pages 285-290

  Relling, Mary V ^a   Pui, Ching Hon ^b   Sandlund, John T ^b   Rivera, Gaston K ^b   Hancock, Michael L ^c   Boyett, James M ^b   Schuetz, Erin G ^a   Evans, William E ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTILEUKEMIC AGENT; ASPARAGINASE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PHENYTOIN; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SEIZURE;

EID: 0034702552     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02503-4     Document Type: Article

References (31)

1. Pui C.H., Evans W.E. Acute lymphoblastic leukemia. N Engl J Med. 339:1998;605-615.
2. Chessells J.M. The management of high-risk lymphoblastic leukaemia in children. Br J Haematol. 108:2000;204-216.
3. Smith M., Arthur D., Camitta B.et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 14:1996;18-24.
4. Steinherz P.G., Gaynon P.S., Breneman J.C.et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response. report from the Childrens Cancer Group J Clin Oncol. 14:1996;389-398.
5. Ochs J.J., Bowman W.P., Pui C-H., Abromowitch M., Mason C., Simone J.V. Seizures in childhood lymphoblastic leukaemia patients. Lancet. ii:1984;1422-1424.
6. Winick N.J., Bowman W.P., Kamen B.A.et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst. 84:1992;252-256.
7. Gentile D.M., Tomlinson E.M., Park B.K., Back D.J. Dexamethasone metabolism by human liver in vitro. metabolite identification and inhibition of 6-hydroxylation J Pharmacol Exp Ther. 277:1996;105-112.
8. Kivisto K.T., Kroemer H.K., Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents. implications for drug interactions Br J Clin Pharmacol. 40:1995;523-530.
9. Relling M.V., Nemec J., Schuetz E.G., Schuetz J.D., Gonzalez F.J., Korzekwa K.R. o-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 45:1994;352-358.
10. Evans W.E., Relling M.V. Pharmacogenomics. translating functional genomics into rational therapeutics Science. 286:1999;487-491.
11. Evans W.E., Relling M.V., Rodman J.H., Crom W.R., Boyett J.M., Pui C.H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 338:1998;499-505.
12. Lennard L., Lilleyman J.S., Van Loon J., Weinshilboum R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 336:1990;225-229.
13. Camitta B., Mahoney D., Leventhal B.et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia. a Pediatric Oncology Group study J Clin Oncol. 12:1994;1383-1389.
14. Evans W.E., Crom W.R., Abromowitch M.et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med. 314:1986;471-477.
15. Rivera G.K., Raimondi S.C., Hancock M.L.et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 337:1991;61-66.
16. Pui C.H., Mahmoud H.H., Rivera G.K.et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 92:1998;411-415.
17. Villikka K., Kivisto K.T., Maenpaa H., Joensuu H., Neuvonen P.J. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther. 66:1999;589-593.
18. Schuetz E.G., Schuetz J.D., Strom S.C.et al. Regulation of human liver cytochromes P450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology. 18:1993;1254-1262.
19. Conney A.H. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 19:1967;317-355.
20. Wassner S.J., Pennisi A.J., Malekzadeh M.H., Fine R.N. The adverse effect of anticonvulsant therapy on renal allograft survival. J Pediatr. 88:1976;134-137.
21. Relling M.V., Hancock M.L., Boyett J.M., Pui C-H., Evans W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 93:1999;2817-2823.
22. Stram D.O., Sather H., Letao W. Analysis of time to death after transplantation when transplants are only given to patients in remission. Biometrics. 52:1996;1079-1086.
23. Baker D.K., Relling M.V., Pui C-H., Christensen M.L., Evans W.E., Rodman J.H. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol. 10:1992;311-315.
24. Rodman J.H., Murry D.J., Madden T., Santana V.M. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol. 12:1994;2390-2397.
25. Reich S.D., Bachur N.R. Alterations in adriamycin efficacy by phenobarbital. Cancer Res. 36:1976;3803-3806.
26. Frey B.M., Frey F.J. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest. 14:1984;1-6.
27. Murphy J.A., Ross L.M., Gibson B.E. Vincristine toxicity in five children with acute lymphoblastic leukaemia. Lancet. 346:1995;443.
28. Nachman J.B., Sather H.N., Sensel M.G.et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 338:1998;1663-1671.
29. Veerman A.J.P., Hahlen K., Kamps W.A.et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. protocol ALL VI, Dutch Childhood Leukemia Study Group J Clin Oncol. 14:1996;911-918.
30. Katki A.G., Kalyanaraman B., Sinha B.K. Interactions of the antitumor drug, etoposide, with reduced thiols in vitro and in vivo. Chem Biol Interact. 62:1987;237-247.
31. Evans W.E., Hutson P.R., Stewart C.F.et al. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther. 33:1983;301-307.